Trial Profile
A Phase II Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Nerve sheath neoplasms; Neurofibrosarcoma
- Focus Therapeutic Use
- 21 Jun 2021 Status changed from active, no longer recruiting to discontinued due to slow enrollment as a result of low incidence of MPNST and the COVID-19 pandemic.
- 15 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2022.